NCT06228482View on ClinicalTrials.gov

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Metastatic Nonsmall Cell Lung Cancer
Interventions
DRUG

[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.

Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.

Trial Locations (1)

95817

RECRUITING

The University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of California, Davis

OTHER